1973
Clinical pharmacology of cyclophosphamide.
Bagley C, Bostick F, DeVita V. Clinical pharmacology of cyclophosphamide. Cancer Research 1973, 33: 226-33. PMID: 4688880.Peer-Reviewed Original Research
1971
Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.
Bray D, DeVita V, Adamson R, Oliverio V. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemotherapy Reports 1971, 55: 215-20. PMID: 5115843.Peer-Reviewed Original ResearchPreliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel C, DeVita V, Denham C, Foley H, Field R, Carbone P. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally. Cancer Chemotherapy Reports 1971, 55: 159-65. PMID: 5118685.Peer-Reviewed Original Research
1970
The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological dispositionThe effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210.
Young R, DeVita V. The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210. Cancer Research 1970, 30: 1789-94. PMID: 5457940.Peer-Reviewed Original ResearchAbnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease
Chabner B, DeVita V, Livingston D, Oliverio V. Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease. New England Journal Of Medicine 1970, 282: 838-843. PMID: 5418547, DOI: 10.1056/nejm197004092821504.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseUntreated patientsPlasma levelsPlasma pyridoxal phosphate levelsPlasma pyridoxal phosphatePyridoxal phosphate levelsAdvanced diseaseComplete remissionSymptomatic diseaseImmunosuppressive effectsAbnormal resultsPyridoxine deficiencyNormal limitsTryptophan metabolismPatientsDiseasePyridoxal phosphatePhosphate levelsDeficiencyL-tryptophanLittle evidenceMetabolismRemissionChemotherapyAnemia
1969
The thymidine-14C and -3H double-labeling technic in the study of the cell cycle of L1210 leukemia ascites tumor in vivo.
Young R, DeVita V, Perry S. The thymidine-14C and -3H double-labeling technic in the study of the cell cycle of L1210 leukemia ascites tumor in vivo. Cancer Research 1969, 29: 1581-4. PMID: 5807231.Peer-Reviewed Original Research